Known targets — ChEMBL curated mechanism
CACNA1CCACNA1DCACNA1FCACNA1SHCN4KCNJ2SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9A
The experimentally established mechanism targets of Dronedarone. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | KCNA5 | P22460 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 0.98 |
| ▸ | PGR | P06401 | 1/20 | 0.98 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.98 |
| ▸ | HTR1A | P08908 | 1/20 | 0.98 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.98 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.98 |
| ▸ | DRD1 | P21728 | 1/20 | 0.98 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.98 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.98 |
| ▸ | PDE4A | P27815 | 1/20 | 0.98 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.98 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.98 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.98 |
| ▸ | DRD3 | P35462 | 1/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.98 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.98 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Dronedarone SCHEMBL18074257 | 1.00 | ABCB11 (1.00) | ABCB11KCNA5ESR1PGRCHRM2 | |
| Dronedarone SCHEMBL29620421 | 1.00 | ABCB11 (1.00) | ABCB11KCNA5ESR1PGRCHRM2 | |
| Dronedarone SCHEMBL28178095 | 0.99 | ABCB11 (0.98) | ABCB11KCNA5ESR1PGRCHRM2 | |
| Dronedarone SCHEMBL322530 | 0.99 | ABCB11 (0.98) | ABCB11KCNA5ESR1PGRCHRM2 | |
| Dronedarone SCHEMBL110363 | 0.99 | ESR1 (1.00) | ABCB11KCNA5ESR1PGRCHRM2 | |
| Dronedarone SCHEMBL4540209 | 0.99 | ESR1 (1.00) | ABCB11KCNA5ESR1PGRCHRM2 | |
| Dronedarone SCHEMBL29533002 | 0.99 | ESR1 (1.00) | ABCB11KCNA5ESR1PGRCHRM2 | |
| Dronedarone SCHEMBL321382 | 0.98 | ESR1 (0.98) | ABCB11KCNA5ESR1PGRCHRM2 | |
| Dronedarone SCHEMBL2472589 | 0.98 | ESR1 (0.98) | ABCB11KCNA5ESR1PGRCHRM2 | |
| Dronedarone SCHEMBL28179052 | 0.98 | ESR1 (0.98) | ABCB11KCNA5ESR1PGRCHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 858 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120154720-A | Application of ATP6V1C1 and inhibitor thereof in preparation of medicines for inhibiting lung cancer metastasis or drug resistance | 四川大学华西医院 | 2025-06-17 | — | — | CN | claimed |
| CN-120136828-A | Preparation method of dronedarone hydrochloride impurity | 南京方生和医药科技有限公司 | 2025-06-13 | — | — | CN | claimed |
| CN-119985817-A | Detection method of dronedarone hydrochloride tablet related substances | 江苏利泰尔药业有限公司 | 2025-05-13 | — | — | CN | claimed |
| CN-119874652-A | Preparation method of dronedarone hydrochloride key intermediate JN-02 | 江苏天士力帝益药业有限公司 | 2025-04-25 | — | — | CN | claimed |
| CN-119868323-A | Application of disulfiram and dronedarone hydrochloride in preparation of drugs for relieving liver injury | 中国人民解放军陆军军医大学第一附属医院 | 2025-04-25 | — | — | CN | claimed |
| US-20250129430-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | VeraVerse Co., Ltd. (KR) | 2025-04-24 | — | — | US | claimed |
| CN-119564659-A | Dronedarone hydrochloride as a polysaccharide application of colistin synergist | 吉林大学 | 2025-03-07 | — | — | CN | claimed |
| US-20240390364-A1 | Novel Pyridine Compositions and their use in methods for preventing or treating diseases, disorders and conditions | REID CHRISTOPHER BRIAN (US) | 2024-11-28 | — | — | US | claimed |
| EP-4442840-A1 | HIGH ATP-AFFINITY PROTEIN AS THERAPEUTIC TARGET FOR INTRACTABLE CANCER MOLECULAR SUBTYPES AND INHIBITOR THEREOF | Veraverse Co., Ltd. (KR) | 2024-10-09 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| EP-2371808-A1 | Process for preparing dronedarone | Ratiopharm GmbH (DE) | 2011-10-05 | — | — | EP | claimed |
| EP-2371824-A1 | Crystalline dronedarone salts | Ratiopharm GmbH (DE) | 2011-10-05 | — | — | EP | claimed |
| US-20080139645-A1 | Solid Pharmaceutical Compositions Containing Benzofuran Derivatives | SANOFI-AVENTIS (FR) | 2008-06-12 | — | — | US | claimed |
| US-7323493-B1 | Solid pharmaceutical composition containing benzofuran derivatives | SANOFI-AVENTIS (FR) | 2008-01-29 | — | — | US | claimed |
| EP-1343473-B1 | PHARMACEUTICAL DRONEDARONE COMPOSITION FOR PARENTERAL ADMINISTRATION | SANOFI AVENTIS (FR) | 2006-12-20 | — | — | EP | claimed |
| US-6939865-B2 | Pharmaceutical dronedarone composition for parenteral administration | SANOFI-AVENTIS (FR) | 2005-09-06 | — | — | US | claimed |
| US-6828448-B2 | 2-butyl-5-(methanesulfonamido)benzofuran; preparation of dronedarone | SANOFI-SYNTHELABO (FR) | 2004-12-07 | — | — | US | claimed |
| EP-1343777-B1 | METHANESULPHONAMIDO-BENZOFURAN, PREPARATION METHOD AND USE THEREOF AS SYNTHESIS INTERMEDIATE | SANOFI SYNTHELABO (FR) | 2004-05-06 | — | — | EP | claimed |
| US-20040048921-A1 | Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate | SANOFI (FR) | 2004-03-11 | — | — | US | claimed |
| US-20040044070-A1 | Pharmaceutical dronedarone composition for parenteral administration | SANOFI (FR) | 2004-03-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040048921-A1 | Methanesulphonamido-benzofuran, preparation method and use thereof as synthesis intermediate | CYP2F1, DHPS, CYP2D6 | ABCB11 521/4885KCNA5 461/4885ESR1 3413/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.